Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases

European Journal of Surgical Oncology

Volumn 34, Issue 11, 2008, Pages 1231-1236

  Kandutsch, S ^a   Klinger, M ^b   Hacker, S ^b   Wrba, F ^a   Gruenberger, B ^c   Gruenberger, T ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

5 Fluorouracil; Chemotherapy; Colorectal cancer liver metastases; Oxaliplatin; Perioperative morbidity; Sinusoidal dilatation

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER METASTASIS; LIVER RESECTION; LIVER SINUSOID; LIVER TOXICITY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STEATOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FATTY LIVER; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORBIDITY; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 53549133451     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.01.001     Document Type: Article

References (24)

1. Hwang P.M., Bunz F., Yu J., et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7 (2001) 1111-1117
2. Laurent A., Nicco C., Chereau C., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65 (2005) 948-956
3. Kohli R., Pan X., Malladi P., et al. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 282 (2007) 21327-21336
4. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
5. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
6. Fong Y., and Bentrem D.J. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243 (2006) 8-9
7. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94 (2007) 274-286
8. Zeiss J., Merrick H.W., Savolaine E.R., et al. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol 13 (1990) 156-160
9. Peppercorn P.D., Reznek R.H., Wilson P., et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77 (1998) 2008-2011
10. Kooby D.A., Fong Y., Suriawinata A., et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
11. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
12. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
13. Pawlik T.M., Olino K., Gleisner A.L., et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11 (2007) 860-868
14. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
15. Bismuth H., and Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 25 (1998) 40-46
16. Allen P.J., Kemeny N., Jarnagin W., et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7 (2003) 109-115
17. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061
18. Tanaka K., Adam R., Shimada H., et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90 (2003) 963-969
19. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
20. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
21. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
22. Kakar S., Kamath P.S., and Burgart L.J. Sinusoidal dilatation and congestion in liver biopsy: is it always due to venous outflow impairment?. Arch Pathol Lab Med 128 (2004) 901-904
23. Wild R., Dings R.P., Subramanian I., and Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 110 (2004) 343-351
24. Nordlinger B., Sorbye H., Collette L., et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol (Meeting Abstracts) 25 (2007) LBA5